Issuance was led by a $2 billion retail pricing from the University of California in the negotiated market and a $1.2 billion competitive deal from Washington.

Dyne Therapeutics Inc (DYN) stock saw a modest uptick, ending the day at $14.55 which represents a slight increase of $0.42 or 2.97% from the prior close of $14.13. The stock opened at $14.3 and ...

BOISE, Idaho - Clearwater Analytics (NYSE: CWAN), known for its investment management and analytics solutions, has been ...

In a report released yesterday, Deane Dray from RBC Capital maintained a Sell rating on 3M (MMM – Research Report), with a price target of ...

In a report released today, Nik Modi from RBC Capital maintained a Buy rating on Monster Beverage (MNST – Research Report), with a price target ...

Shares of Snam SPA (MI:SRG) climbed 1.5% following the release of their strategic plan for 2025-2029, which outlined a higher-than-expected capital expenditure plan and an increase in their dividend ...

Barry Callebaut (SIX: BARN) reported lower sales volume in the first quarter of their 2025 fiscal year, as expected by the ...

By Nell Mackenzie, Carolina Mandl and Summer Zhen LONDON (Reuters) -Hedge funds have positioned for Donald Trump's U.S.